INTRODUCTION {#SEC1}
============

High-throughput sequencing methods are generating a huge amount of genomic data ([@B1]), and full genome and exome sequencing techniques have greatly enhanced our knowledge about human genetic variation ([@B2]--[@B4])). Since information is available for healthy individuals ([@B5]) as well as for patients suffering from various diseases ([@B6]), it is possible to analyse the differences between neutral variants, which are present in a control population and are thus considered benign, and deleterious variants, which lead to a disease phenotype. This copious data stream requires efficient processing and annotation to be useful, and in the case of human genetic diseases, efficient computational methods are necessary to reduce the number of observed variants to a few that are likely causative for the phenotype under scrutiny ([@B2],[@B3],[@B7]). Many computational tools for identifying these deleterious variants have been developed so far ([@B8]). Although these tools tackle the prediction of the pathogenicity of variants from different angles, they generally use Machine Learning (ML) or statistical methods to learn a discrimination between deleterious and neutral Single Nucleotide Variants (SNVs) resulting in amino-acid substitutions at the protein level ([@B9]--[@B13]). These predictors generally consider different molecular or protein-level aspects that are closely related to possible mechanisms of pathogenicity, such as the evolutionary conservation of the mutated position ([@B9],[@B10]), the stability change upon mutation ([@B14]), possible structural alterations ([@B9],[@B14]) and functional annotations using GO terms ([@B13]). With DEOGEN ([@B12]) we introduced contextualization of the target variants by combining sources of information related to different biological scales, with the aim to better represent the complexity of the relationship between variants and their pathogenicity. We integrated information such as the molecular effect of the variant, the relevance of the mutated gene, its known interaction and the pathways in which it is involved. We showed that this approach improves the quality of the final predictions, but our model did not explain how the final deleteriousness score relates to the other variants on the same protein and where it programmatically originates from.

We here present DEOGEN2, a predictor of missense SVNs for human proteins that is freely accessible at <http://deogen2.mutaframe.com/>. DEOGEN2 positively compares with other state-of-the-art methods ([@B9],[@B12],[@B15]--[@B17]) through the further incorporation of various sources of contextual information, such as early folding predictions and protein domain-oriented features. This performance improvement is confirmed on an independent dataset, evidencing the robustness of DEOGEN2. In addition, we provide interactive visualisation approaches to (i) explain how the deleteriousness score relates to all other variants within that protein and (ii) break down the origin of the score, so enabling the non-expert user to situate the prediction result in its wider biological context. This development enables geneticists and clinicians to move beyond the identification of new disease-causing variants towards their interpretation.

MATERIALS AND METHODS {#SEC2}
=====================

Datasets {#SEC2-1}
--------

The main training and testing **Humsavar16** dataset for DEOGEN2 is based on the February 2016 version of Humsavar ([@B18]). From the original 73 266 variants mapped on 12 335 proteins, 7375 unclassified variants were discarded and 27 606 deleterious SNVs and 38 285 neutral SNVs retained. In addition, an independent **Blind** dataset based on Testing Dataset I proposed in ([@B8]), which contains 120 deleterious variants extracted from 57 Nature Genetics publications and 124 neutral variants from ([@B5],[@B8]), was created by filtering out 30 proteins also present in **Humsavar16**, so ensuring complete independence between these datasets.

Features {#SEC2-2}
--------

The DEOGEN2 features are listed in Table [1](#tbl1){ref-type="table"}; we present only the new and improved features compared to DEOGEN ([@B12]).

###### Summary of the features used in DEOGEN2

  Feature                                   Status           Short name   Code
  ----------------------------------------- ---------------- ------------ ------
  PROVEAN score ([@B16])                    From version 1   PROV         PR
  Conservation Index ([@B12],[@B13])        Improved         CI           CI
  Mutant/wildtype log-odd ratio ([@B12])    Improved         LOR          LO
  Early Folding predictions                 New              EF           EF
  PFAM log-odd score ([@B17])               New              PF           PF
  Interaction patches annotation ([@B19])   New              INT          IN
  RVIS ([@B20])                             New              RVIS         RV
  GDI ([@B21])                              New              GDI          GD
  Recessiveness index ([@B22])              From version 1   REC          RE
  Gene essentiality ([@B23])                From version 1   ESS          ES
  Pathway log-odd score ([@B12],[@B13])     Extended data    PATH         PA

### Evolutionary-based features {#SEC2-2-1}

The evolutionary-based **CI** (Conservation Index) and **LOR** (Log-Odd Ratio) scores ([@B12]) were improved by switching to hhBlits ([@B24]) from JackHmmer ([@B25]) to generate Multiple Sequence Aligments (MSAs), resulting in (i) MSAs that are faster to compute, (ii) the retrieval of more distant homologs and (iii) generally smaller alignments. The hhBlits MSAs were computed with one iteration and *E*-value =10^−4^, and we added a pre-filtering step to the MSAs before computing CI and LOR scores by removing the sequences with \<0.3 coverage and 0.3 Sequence Identity (SI) from the LOR calculation and with \<0.1 coverage and 0.1 SI from the CI computation (see [Supplementary Section S1](#sup1){ref-type="supplementary-material"} and [Figures S1 and S2](#sup1){ref-type="supplementary-material"}).

### Early folding predictions {#SEC2-2-2}

Disruptions to the protein folding process are likely to deactivate the function of proteins that should fold. We added a prediction of protein Early Folding (**EF**) residues as a feature in DEOGEN2 to explore this type of molecular information in variant-effect prediction. This method uses predictions from DynaMine ([@B26]) in combination with a Support Vector Machine (SVM) model trained on the data from the Start2Fold dataset ([@B27]) to make its predictions (under review). For each variant the EF is calculated and the difference with the wild type prediction taken as a measure for the impact on the initial steps of the protein\'s folding process (see [Supplementary Figure S3](#sup1){ref-type="supplementary-material"}).

### Domain-oriented feature {#SEC2-2-3}

PfamScan ([@B28]) was used to obtain domain boundaries and other PFAM ([@B29]) annotations such as coiled-coil regions, repeats, motifs or disordered regions. Similar to ([@B12],[@B13],[@B17]), the training set was used in cross-validation settings to learn the log-odd ratio of the probability of observing a deleterious or a neutral variant on each PFAM entry (see [Supplementary Section S2](#sup1){ref-type="supplementary-material"} for details). This **PF** scores provide an indication of the tendency of these entries to be involved in deleterious phenotypes (see [Supplementary Figure S4](#sup1){ref-type="supplementary-material"}).

### Interaction patches {#SEC2-2-4}

Annotations on 11 471 known interaction patches for 3627 human proteins were obtained from the INstruct database ([@B19]). For every pair of interacting proteins, INstruct contains an indication of where the interaction patch in each protein, identified from the structure of the complex, is situated in the sequence. Information about whether the variant occurs on a known interaction patch (or not) was included as the **INT** feature (see [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}).

### Gene-oriented features {#SEC2-2-5}

The Residual Variation Intolerance Score (**RVIS**) ([@B20]) and Gene Damage Index (**GDI**) ([@B21]) scores improve the contextualization of whether a variant affects a gene/protein important for human health. GDI is a gene-level metric of the cumulative mutational damage that each gene carries in the general population ([@B21]). Since natural selection acts on genes in function of their relevance for human health, the most frequently mutated genes are more likely to harbor nearly-neutral variants, while variants on least damaged genes are more likely to be disease-related ([@B21]). RVIS ([@B20]) ranks the likelihood of the genes to be disease-causing by comparing the amount of functional variation carried by each gene with respect to the genome-wide average. Genes with low common functional variation are more subject to purifying selection than genes with a higher than average mutational burden, highlighting their functional relevance. (see [Supplementary Figures S6 and S7](#sup1){ref-type="supplementary-material"})

### Pathway-oriented feature {#SEC2-2-6}

We updated the snp&Go ([@B13]) inspired pathway log-odd score with data from version 31 of ConsensusPathDB ([@B30]), which now contains 4012 human pathways and 131 216 proteins. As previously ([@B12]), we learned the log-odd scores for each pathway in cross-validation settings to obtain new **PATH** scores that are a proxy of the pathways' sensitivity to deleterious variants.

Machine Learning and Validation {#SEC2-3}
-------------------------------

We contextualized each variant with the features described above, so obtaining 11-dimensional feature vectors for each variant. We used the scikit-learn ([@B31]) implementation of a Random Forest ([@B32]) classifier with 200 trees. The performances on the Humsavar16 dataset were computed in strict 10-fold cross-validation settings. To reduce possible over-fitting due to homologies between proteins in different cross-validation sets, we ensured that proteins in each set share \<25% sequence similarity with the proteins in the other nine sets. The RF model was analysed using the `treeinterpreter` library (<https://github.com/andosa/treeinterpreter>), which decomposes each prediction into its feature contributions (see [Supplementary Section S3](#sup1){ref-type="supplementary-material"}). The final model used in the webserver has been trained on the entire Humsavar16 dataset.

Visualization {#SEC2-4}
-------------

The server framework uses the lexicon visualization library, a collection of micro-libraries written using javascript (es5) and the D3 library (v3.5.17) ([@B33]). Each micro library operates on JSON formatted input. Programmatic access to the methods within each visualization object allows user-control and automated synchronization between different objects.

RESULTS {#SEC3}
=======

Extended contextualization improves the predictions {#SEC3-1}
---------------------------------------------------

The relationship between a variant and the phenotypic outcome at the human individual level involves an extensive network of interactions and feedback that spans different biological scales, from the molecular to organs. An accurate prediction of the deleteriousness of a variant should encompass such information: we therefore improved and extended the multi-level biological contextualization of the target variants and the affected proteins within our model ([@B12]). In particular, we reduced the requirements in terms of homologous sequences in the MSAs to compute the CI and LOR features and improved the REC, ESS and PATH knowledge based features due to dbNFSP ([@B34]) and ConsensusPathDB ([@B30]) updates. We also introduced new strategic pieces of information as features that (i) provide information about the relevance of the mutated residues for the initial steps of the protein\'s folding process (EF), (ii) quantify the sensitivity of the domain affected by the mutation to deleterious variants (PF) and (iii) improve the gene-level assessment of the relevance of the mutated protein for human health. The incremental contributions of these features are shown in [Supplementary Table S1](#sup1){ref-type="supplementary-material"} and the distributions of their contributions in the final prediction are shown in [Supplementary Figures S8--S18](#sup1){ref-type="supplementary-material"}.

Comparison with other methods {#SEC3-2}
-----------------------------

We compared the DEOGEN2 performance with the current state-of-the-art on the **Humsavar16** dataset for 10 predictors, and on the **Blind** dataset for 14 predictors. The DEOGEN2 performances on **Humsavar16** (Table [2](#tbl2){ref-type="table"}) show that it has the highest Balanced Accuracy (BAC) and the highest MCC, alongside with metaSVM. Note that the performances of the other methods were extracted from dbNSFP ([@B34]) and may be over-estimated since their training set may overlap with Humsavar16, whereas the DEOGEN2 performances were computed in strict cross-validation settings. DEOGEN2 also performs 7% better than our previous DEOGEN model in terms of MCC. On the independent **Blind** dataset ([@B8]), DEOGEN2 has the highest BAC and the highest MCC (Table [3](#tbl3){ref-type="table"}), with the performances of 13 predictors as reported in ([@B8]), plus the recently published M-CAP ([@B35]) included.

###### Comparison of DEOGEN2 cross-validated performances with state of the art predictors on the Humsavar16 dataset

  Method             Sen      Spe      Bac      Pre      MCC
  ------------------ -------- -------- -------- -------- --------
  PolyPhen2          85       73       79       71       57
  LRT                84       70       77       70       54
  MutationTaster     **94**   70       82       70       63
  MutationAssessor   81       71       76       69       52
  fatHMM             78       85       82       80       63
  PROVEAN            82       75       79       72       57
  metaSVM            83       **93**   88       **90**   **76**
  fatHMM-MKL         **94**   54       74       61       51
  SIFT               85       68       77       67       53
  PON-P2             86       83       84       80       69
  VEST3              88       87       87       82       74
  DEOGEN             77       92       84       85       71
  **DEOGEN2**        89       88       **89**   84       **76**

DEOGEN and DEOGEN2 scores have been computed in-house with a stratified 10-folds cross-validation. DEOGEN2 uses the MCC-optimal deleteriousness threshold \>0.45. PON-P2 predictions have been obtained from its web server. All the other scores have been extracted from the 3.2 version of dbNSFP ([@B34]).

###### Predictor performances on the Blind dataset

  Method              Sen      Spe      Bac      Pre      MCC
  ------------------- -------- -------- -------- -------- --------
  SIFT                68       75       72       79       43
  PolyPhen2 (HVAR)    88       67       78       78       57
  LRT                 88       66       77       78       57
  Mutation Taster     **94**   74       84       83       70
  Mutation Assessor   70       80       75       83       49
  FatHMM              55       91       73       90       48
  GERP++              77       72       75       80       49
  PhyloP              76       73       75       80       49
  SNAP                53       70       62       63       23
  SNP&GO              55       94       75       89       53
  MutPred             74       81       78       79       55
  CONDEL              71       73       72       72       44
  CADD phred          79       74       77       81       53
  M-CAP               93       68       81       74       63
  DEOGEN              46       **96**   71       **92**   48
  **DEOGEN2**         87       86       **87**   87       **73**

DEOGEN2 scores were computed in-house using the deleteriousness threshold \>0.5. M-CAP ([@B35]) scores were downloaded and interpreted using pathogenicity threshold \>0.025. All other scores from ([@B8]).

Visualization of the results {#SEC3-3}
----------------------------

The DEOGEN2 visualisation process and graphs are described in Figure [1](#F1){ref-type="fig"}. A sample variant can be loaded by clicking on the 'Load Example' button: this displays the N45S variant in Transforming Growth Factor-Beta Receptor 1 (TGFBR1), with Uniprot ID P36897 and RefSeq ID NP_004603.1. Variants of this protein have been linked to Loeys-Dietz Syndrome and susceptibility to multiple self-healing squamous epithelioma ([@B36],[@B37]), and we will discuss the information that the web server provides around this example of a disease-causing variant.

![Overview of the DEOGEN2 web server visualization. (1) The user starts to enter a Uniprot ID or sequence, which activates a dropdown list from which a human protein is selected. After pressing the play button, the user can navigate the sequence (2) to create and submit a variant for this sequence. After pressing 'Submit sequence', the variant is visualized in the page report (3) which contains two sections. The General section displays the change between the wild-type and variant amino acid, with the chemical structures of both shown, and the difference between the amino acids expressed on (**A**) the dashboard as a percentage; clicking on the percentage bar will show the breakdown of these components. The DEOGEN2 section shows the DEOGEN2 score with (**B**) a breakdown of the contribution of each machine learning feature, so informing the user about which contextual information was most important to reach the final score, and an overview of the raw features scores used as input for the machine learning. Section (**C**) shows the distribution of all the variant scores in this protein, including in a heat map format (not shown). Information on data points is obtained by hovering over them, the visualization can be changed by clicking on the buttons or the graph icon in the top right corner.](gkx390fig1){#F1}

The 'General' section of the page report (Figure [1](#F1){ref-type="fig"}.3) shows that the amino acids are relatively similar; both are polar and hydrophilic amino acids with only a small size difference. The calculation of the percentages here is based on a normalised score of the differences in the BLOSUM62 matrix change, the amino acid size, hydrophobicity and charge. Despite the similarity of the amino acids, the 'DEOGEN2' section shows that this variant is likely deleterious with an overall score of 0.927 (0 is benign, 1 is deleterious, with the prediction cutoff point at 0.5). The dashboard highlights the key features that contributed to this score; clicking on the percentage bar will display a breakdown of these components.

The first graph underneath (Figure [1](#F1){ref-type="fig"}.Breakdown) shows the machine learning contributions in detail: on the x-axis each feature code is listed (Table [1](#tbl1){ref-type="table"}), while the y-axis indicates the contribution of the corresponding feature toward the final decision: positive values vote toward deleteriousness, negative values toward a benign variant (see [Supplementary Section S3](#sup1){ref-type="supplementary-material"}). Clicking on the top-right graph button will link the points to better illustrate the decision profile for the variant of interest. In the case of variant N45S, the plot indicates that, among the evolutionary features, PROVEAN (PR) pushed the decision towards the deleterious class while CI (CI) and LOR (LO) slightly pushed towards neutrality. This behavior highlights the complementarity of the different evolutionary features used in our model: in this case the wider sequence context (PR) points to deleteriousness of the variant, not its individual position in the sequence. The contribution of the PFAM log-odd score (PF) strongly pushed the decision towards the deleterious class, due to the fact that N45S variant falls into the Activin receptor domain (PF01064.20), whose sensitivity to deleterious variants is reasonably high (log-odd score of 1.79). Among the protein-oriented features, only REC (RE) provided a noticeable contribution, indicating this protein is encoded by a gene that can cause recessive disorders when homozygously lost.

The next graph shows the raw feature scores that are the input for the prediction algorithm. Next, the distribution of the scores of all the variants in the same protein is shown (Figure [1](#F1){ref-type="fig"}.Distribution), with the y-axis showing the frequency and the x-axis the overall DEOGEN2 score. Clicking on the marker button enables the user to evaluate where their variant is situated in this distribution; in the case of TGFBR1, the protein contains variants predicted as deleterious but a larger proportion has scores below the 0.5 threshold and are therefore likely benign. By clicking on the 'Local' button the user can scroll through the sequence to see where the most deleterious or benign regions are located. The sequence position can be identified by hovering over the yellow highlighted sections. For example, the region around residue 193 is highly deleterious, whereas variants in the region around residue 360 are likely benign. Finally, this information is represented in a heat map that visualizes all variants for each sequence position. This enables the user to identify 'hot spots' in the sequence, and pinpoint which amino acid variants are predicted as the most deleterious.

DISCUSSION AND CONCLUSION {#SEC4}
=========================

With the continuing performance improvement of variant effect predictors, partially due to the integration of increasing amounts of data at different biological levels, we think the time is right to shift their focus to the what, how and where, so generating understanding about what the variant means. With the DEOGEN2 webserver, we provide visualization of the meaning, protein context and origins of each prediction to enable the user to make a more informed decision or hypothesis about a particular variant instead of having to rely on a single all-encompassing score.

Supplementary Material
======================

###### 

Click here for additional data file.
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[Supplementary Data](#sup1){ref-type="supplementary-material"} are available at NAR Online.
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